Last updated: February 13, 2026
What is the current market status of the drug NDC 00713-0720?
The drug NDC 00713-0720 is Clarithromycin, used primarily for bacterial infections. Its market includes conditions like respiratory tract infections, skin infections, and Helicobacter pylori-associated ulcers.
As of 2023, Clarithromycin remains a high-demand antibiotic, especially in regions with high rates of bacterial resistance and where newer alternatives are less accessible. The generic form dominates the market, with branded versions primarily from Abbott (Biaxin). The drug's sales peaked in 2015 but have stabilized given the rise of antibiotic resistance and formulary shifts.
How does the patent landscape influence market access?
Clarithromycin's original patent expired in 2004, leading to widespread generic manufacturing. No current patents limit generic production, resulting in a competitive landscape:
- About 15 generic manufacturers hold approved equivalents.
- Price competition has kept the average wholesale price (AWP) low, around $0.30 to $0.50 per 500 mg tablet.
- Some countries have pricing controls limiting maximum retail prices.
Market size (2023)
| Region |
Estimated Market Value |
Population |
Key Factors |
| United States |
$250 million |
330 million |
High antibiotic resistance, formulary preferences |
| Europe |
$180 million |
747 million |
Reimbursement policies, resistance patterns |
| Rest of World |
$150 million |
4.8 billion |
Limited access, generics dominate, price sensitivity |
What are the analytics and trends dictating future pricing?
Pricing trends
- Current retail price: $0.30 to $0.50 per tablet
- Projected price decline: Approximately 2% annually due to increased generic competition.
- Price stabilization: Expected over next 2 years as generic brands saturate markets.
Key market drivers
- Antibiotic resistance reduces clinical utility, impacting sales volume.
- Policy shifts favoring antibiotic stewardship limit prescribing.
- Emerging alternatives like azithromycin and doxycycline gain prominence, substituting Clarithromycin in certain indications.
- Patent expiries for certain formulations after 2004, increasing generics' influence.
Regulatory dynamics
- The U.S. FDA approved several generics since 2004, ensuring ongoing availability.
- Price controls in European markets via national health institutions.
Investment and R&D prospects
- Limited R&D pipelines for new Clarithromycin formulations; focus shifts to combination therapies.
- No recent patent filings indicate minimal innovation focus presently.
What are the key price projection figures?
| Year |
Estimated Price per 500 mg Tablet |
Notes |
| 2023 |
$0.30 - $0.50 |
Current range based on market data |
| 2024 |
$0.29 - $0.48 |
Slight decline driven by increased competition |
| 2025 |
$0.28 - $0.46 |
Market saturation with generics; price stabilization expected |
| 2026 |
$0.27 - $0.45 |
Continuing downward trend with stabilization projected |
What is the outlook for market growth?
The market for Clarithromycin has experienced a CAGR of approximately -2% over the last five years due to increasing resistance and substitution by other antibiotics. Future growth is expected to remain flat or decline slightly as health systems emphasize antibiotic stewardship and alternative therapies.
An increased focus on reducing antibiotic resistance may result in decreased prescribing, potentially shrinking the market by 1-2% annually over the next five years. However, demand persists in developing markets with less stringent regulations and limited access to newer antibiotics.
What are the implications of this analysis for stakeholders?
Manufacturers: Focus on cost efficiencies in generic production; minimal innovation is expected.
Investors: Stability in pricing and sales volume is maintained in stable markets; look for opportunities in regions with limited access to newer drugs.
Policy Makers: Continued emphasis on stewardship may further restrict usage, impacting market volume.
Pharmaceutical R&D: R&D activity is unlikely to increase significantly for Clarithromycin unless new resistant strains emerge or novel formulations are developed.
Key Takeaways
- Clarithromycin’s market is mature with aggressive generics competition controlling pricing.
- Price per tablet is expected to decline marginally over the next three years.
- The overall market volume is decreasing due to resistance issues and alternative antibiotics.
- The absence of recent patent protections limits innovation incentives.
- Growth prospects favor emerging markets with unmet needs and limited access to newer antibiotics.
FAQs
1. Will Clarithromycin see significant price increases?
No. Patent expirations and generics domination suppress the potential for price increases.
2. Are branded versions likely to maintain higher prices?
Limited. Branded versions like Biaxin typically price slightly above generics but are rarely dominant in pricing since generics are widely available.
3. How is antibiotic resistance affecting the market?
Rising resistance diminishes clinical utility, leading to reduced prescribing and impacting overall sales volume.
4. Is there ongoing R&D for new Clarithromycin formulations?
Research focus has shifted toward combination therapies and newer antibiotics; minimal innovation is ongoing for Clarithromycin itself.
5. What regions present the most promising markets for Clarithromycin?
Developing markets with limited access to newer antibiotics and weaker regulatory controls.
Sources
[1] IQVIA. International Pharmaceutical Market Data, 2023.
[2] FDA Orange Book, 2023.
[3] European Medicines Agency. Summary of Product Characteristics, 2023.
[4] Sanford Guide to Antimicrobial Therapy, 2023.
